StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) stock

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30285% above fair value
$143.37−1.09 (-0.75%)

Close on Nov 17, 2026Market cap $353.72BP/E 114.7Yield 2.29%

Merck cash

Cash and short-term investments held at the end of each period.

Merck's cash was $7.14B at Jun 30, 2026. For fiscal 2025 it was $14.57B, up 5.8% from the year before. Over ten years it grew 0.8% a year on average. The highest annual figure on record is $17.49B in fiscal 2013.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.57B+5.8%
FY2024Dec 31, 2024$13.77B+92.2%
FY2023Dec 31, 2023$7.16B-46.0%
FY2022Dec 31, 2022$13.27B+62.5%
FY2021Dec 31, 2021$8.17B+0.2%
FY2020Dec 31, 2020$8.15B-23.9%
FY2019Dec 31, 2019$10.71B+20.8%
FY2018Dec 31, 2018$8.87B+4.3%
FY2017Dec 31, 2017$8.50B-40.7%
FY2016Dec 31, 2016$14.34B+6.8%
FY2015Dec 31, 2015$13.43B-14.6%
FY2014Dec 31, 2014$15.72B-10.1%
FY2013Dec 31, 2013$17.49B+8.3%
FY2012Dec 31, 2012$16.14B+7.8%
FY2011Dec 31, 2011$14.97B+22.7%
FY2010Dec 31, 2010$12.20B+27.0%
FY2009Dec 31, 2009$9.60B+75.1%
FY2008Dec 31, 2008$5.49B+2.8%
FY2007Dec 31, 2007$5.34B-9.8%
FY2006Dec 31, 2006$5.91B–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$7.14B-17.8%
Q1 FY2026Mar 31, 2026$5.70B-38.9%
Q4 FY2025Dec 31, 2025$14.57B+5.8%
Q3 FY2025Sep 30, 2025$18.21B+24.0%
Q2 FY2025Jun 30, 2025$8.69B-23.9%
Q1 FY2025Mar 31, 2025$9.33B+63.4%
Q4 FY2024Dec 31, 2024$13.77B+92.2%
Q3 FY2024Sep 30, 2024$14.69B+66.2%
Q2 FY2024Jun 30, 2024$11.42B+77.7%
Q1 FY2024Mar 31, 2024$5.71B-45.4%
Q4 FY2023Dec 31, 2023$7.16B-46.0%
Q3 FY2023Sep 30, 2023$8.84B-22.4%
Q2 FY2023Jun 30, 2023$6.43B-37.0%
Q1 FY2023Mar 31, 2023$10.47B+16.5%
Q4 FY2022Dec 31, 2022$13.27B+62.5%
Q3 FY2022Sep 30, 2022$11.38B+13.3%
Q2 FY2022Jun 30, 2022$10.21B+18.3%
Q1 FY2022Mar 31, 2022$8.99B+30.6%
Q4 FY2021Dec 31, 2021$8.17B+0.2%
Q3 FY2021Sep 30, 2021$10.05B+35.7%
Q2 FY2021Jun 30, 2021$8.63B-22.6%
Q1 FY2021Mar 31, 2021$6.88B-7.8%
Q4 FY2020Dec 31, 2020$8.15B-23.9%
Q3 FY2020Sep 30, 2020$7.40B-7.7%
Q2 FY2020Jun 30, 2020$11.15B+56.9%
Q1 FY2020Mar 31, 2020$7.47B-15.1%
Q4 FY2019Dec 31, 2019$10.71B+20.8%
Q3 FY2019Sep 30, 2019$8.02B-22.0%
Q2 FY2019Jun 30, 2019$7.11B-6.5%
Q1 FY2019Mar 31, 2019$8.80B+19.7%
Q4 FY2018Dec 31, 2018$8.87B+4.3%
Q3 FY2018Sep 30, 2018$10.29B-8.1%
Q2 FY2018Jun 30, 2018$7.60B-36.5%
Q1 FY2018Mar 31, 2018$7.35B-51.8%
Q4 FY2017Dec 31, 2017$8.50B-40.7%
Q3 FY2017Sep 30, 2017$11.20B-14.3%
Q2 FY2017Jun 30, 2017$11.97B–
Q1 FY2017Mar 31, 2017$15.25B–
Q4 FY2016Dec 31, 2016$14.34B–
Q3 FY2016Sep 30, 2016$13.07B–

More Merck figures

See a number that looks wrong?